Iqure Pharma Inc

iQure is a clinical-stage biotech company advancing a new therapeutic approach for CNS disorders by restoring glutamate homeostasis. Our science targets one of the core functions of astrocytes: the regulation of glutamate uptake, essential for maintaining synaptic balance and protecting neurons from overstimulation. By enhancing the function of the main transporter involved in this process, we break the cycle of excitotoxicity, a feedback loop that drives neuronal damage and disease progression across a broad range of CNS conditions. Our lead asset, iQ-007, is a first-in-class, orally available small molecule that enhances the activity of the main glutamate transporter. Currently in Phase 1 clinical development for treatment-resistant epilepsy, iQ-007 provides the first clinical validation of our approach. Beyond epilepsy, we are advancing additional preclinical programs targeting neurodegeneration and pain.